Bladder Tumor clinical trials

Explore recruiting bladder tumor clinical trials.

Recruiting bladder tumor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Bladder Tumor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer. (CA209-6E8, CNN-BC trial)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective randomised study of the impact of preoperative administration of mitomycin-C by electromotive drug administration (EMDA) in patients with non-muscle invasive urothelial carcinoma

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)

France, Denmark, Spain, Czechia, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non-inferiority, Phase IV, Open-label, Randomized Controlled Trial of primary Photodynamic Trans-urethral Resection of Bladder Tumors (PDD-TURBT) versus conventional white-light TURBT plus Repeated-TURBT (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) candidate for second look and resection

Italy

Therapeutic use (Phase IV) EU CTIS Study details

Bladder Tumor trials by city

Bladder Tumor in Toronto Bladder Tumor in Vancouver Bladder Tumor in Montreal Bladder Tumor in Calgary Bladder Tumor in Edmonton Bladder Tumor in Ottawa Bladder Tumor in Winnipeg Bladder Tumor in Quebec City Bladder Tumor in Hamilton Bladder Tumor in Kitchener Bladder Tumor in London Bladder Tumor in Halifax Bladder Tumor in New York Bladder Tumor in Los Angeles Bladder Tumor in Chicago Bladder Tumor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease